PF-06952229

小分子

1KKS7U3X86 | SCHEMBL16879380 | 3-Pyridinecarboxamide, 4-((2-(5-chloro-2-fluorophenyl)-5-(1-methylethyl)-4-pyridinyl)amino)-N-(2-hydroxy-1-(hydroxymethyl)ethyl)- | AKOS040734464 | PF06952229 | PF-06952229 | MS-28403 | PF 06952229 [WHO-DD] | BDBM280355 | Sy

PF-06952229

P649080-5mg

5mg

≥99%

-20°C储存

超低温冰袋运输

PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer In Vivo PF-06952229 (oral gavage; 30 mg/kg; twice daily; 21 days) combines with Palbociclib 21 days results in an improved inhibition of pSMAD2 in the MCF7 ER + xenograft breast cancer tumor model. This combination also leads to a significant increase in survival relative to PF-06952229 monotherapy . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MCF-7 ER + HER2-xenograft breast cancer tumor model Dosage: 30 mg/kg Administration: Oral gavage; twice daily; 44 days Result: Resulted in an increase in tumor growth inhibition when combined with Palbociclib. Form:Solid IC50& Target:IC50: transforming growth factor-beta receptor 1 (TGFbR1)

PF-06952229 是一种强效、选择性和口服活性 TGFbR1 抑制剂。PF-06952229 能特异性地与 TGFbR1 结合，阻止 TGFbR1 介导的信号转导。

1801333-55-0

C23H24ClFN4O3

458.91 g/mol

118211239

CC(C)C1=CN=C(C=C1NC2=C(C=NC=C2)C(=O)NC(CO)CO)C3=C(C=CC(=C3)Cl)F

4-[[2-(5-chloro-2-fluorophenyl)-5-propan-2-ylpyridin-4-yl]amino]-N-(1,3-dihydroxypropan-2-yl)pyridine-3-carboxamide

1S/C23H24ClFN4O3/c1-13(2)17-10-27-21(16-7-14(24)3-4-19(16)25)8-22(17)29-20-5-6-26-9-18(20)23(32)28-15(11-30)12-31/h3-10,13,15,30-31H,11-12H2,1-2H3,(H,28,32)(H,26,27,29)

IPBLCOKXDQHSQW-UHFFFAOYSA-N

CC(C)C1=CN=C(C=C1NC2=C(C=NC=C2)C(=O)NC(CO)CO)C3=C(C=CC(=C3)Cl)F

118211239

1801333-55-0

DMSO : 50 mg/mL (108.95 mM; Need ultrasonic)

4

7

8

458.152 Da

458.152 Da

107.000 Ų

32

0

598.000

0

1

3.400